medigraphic.com

2015, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (2)

Atypical presentation of diffuse large B-cell non- Hodgkin lymphoma

Alcocer-Gamba MA, León-González S, Castro-Montes E, Loarca-Piña LM, Lugo-Gavidia LM, García-Hernández E

Language: Spanish
References: 20
Page: 232-238
PDF size: 96.13 Kb.


ABSTRACT

The non-Hodgkin lymphoma is a neoplastic entity that presents in extranodal form in 20 % of cases, usually occurs as solitary or generalized lymphadenopathy. There may be misdiagnosis if it manifests as primary extranodal disease because the primary infiltration may occur with different organs, despite the diffi culty of diagnosis of primary extranodal location of non-Hodgkin lymphoma, histological and immunohistochemical studies are effective in preventing misdiagnosis.
The presentation of this case is to describe this condition in its extranodal variety with cardiac infiltration in a 23 year-old woman with progressive dyspnea. Tumor mass was detected in right-atrial, venous catheterization biopsy was performed, this enabled the histopathological diagnosis and establish treatment. We present experiences from the attention of the case and review of the literature with special reference to diagnosis and treatment.


REFERENCES

  1. Sánchez de Toledo-Codina J. Linfomas. Linfoma de Hodgkin y linfoma no Hodgkin. Pediatr Integral. 2008;XII(6):563-72.

  2. Vela-Casas F. Linfomas no-Hodgkin y enfermedad de Hodgkin. Pediatr Integral. 2004;VIII(6):475-86.

  3. Evans L, Hancok BW. Non-Hodgkin lymphoma. Lancet. 2003;362(9378):139-46

  4. Ruiz Arguelles G. Fundamentos de Hematología. 4ª ed. México: editorial medica panamericana; 2009.

  5. Ballesteros del Rio B, Barbón M, Muela-MolineroA, Fuertes M. Enfermedad de Hodgkin de localización primaria extraganglionar. An Med Interna. 2003; 20(2):55-56. Laurie H. Sehn. Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma Hematology Am Soc Hematol Educ Program. 2006:295-302.

  6. Sehn LH. Optimal use of prognostic factors in non- Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006:295-302. Texto libre en http://asheducationbook.hematologylibrary.org/ content/2006/1/295.longhttp://asheducationbook. hematologylibrary.org/content/2006/1/295.long

  7. Essadi I, Tazi EM, Allam W, Sbitti Y, Ichou M, Erriani H. Primary non Hodgkin’s lymphoma of the orbit: A case report. Med Case Stud 2011;2(2):19-21

  8. Flox A, Hernández F, Salguero R, Sánchez I, Carbonell A, Tascón J. Linfoma cardiaco primario: diagnóstico mediante biopsia transyugular. Rev Esp Cardiol 2003;56(11):1141-44. Texto libre en http://www.revespcardiol.org/es/linfoma-cardiacoprimario- diagnostico-mediante/articulo/13054042/

  9. Gowda M, Khan IA. Clinical perspectives of primary cardiac lymphoma. Angiology. 2003;54(5):599-604.

  10. Porcar C, Clemente C, Garcia D, Guardia R, Pérez J, García-Bragado F. Linfoma cardiaco primario: diagnóstico citológico y tratamiento con respuesta a poliquimioterapia y a autotrasnsplante de precursores hematopoyéticos. Presentación de un caso y revisión de la literatura. An Med Interna. 2002;19(6): 305-309.

  11. de la Torre J, Mayayo E, Fernández F. Varón con masa intracardiaca e insufi ciencia cardíaca. Rev Esp Patol. 2003;36(3):339-46.

  12. Fuzellier JF, Saade YA, Torossian PF, Baehrel B. Primary cardiac lymphoma: diagnosis and treatment. Report of 6 cases and review of the literature. Arch Mal Coeur Vaiss. 2005;98(5):875-80. 238 Alcocer-Gamba MA et al. Linfoma no Hodgkin difuso en células B grandes Rev Med Inst Mex Seguro Soc. 2015;53(2):232-8

  13. Lee SP, Choi EK, Kim TM, Park EA, Kim HK, Cho HJ, et al.Multimodality Imaging can help to doubt, diagnose and follow-up cardiac mass. Korean Circ J. 2011;41(9):555-58. Texto libre en http://www.ncbi. nlm.nih.gov/pmc/articles/PMC3193050/

  14. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classifi cation of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5): 1361-92. Texto libre en http://www. bloodjournal.org/content/84/5/1361.full.pdf+html

  15. Cigarroa J, García Y, Yáñez L, Jiménez S, Martínez A, Ortegón J, et al. Rabdomioma cardiaco tratado quirúrgicamente con éxito y revisión de la literatura. Arch Cardiol Mex. 2005;75(Supl 3):113-117. Texto libre en http://www.scielo.org.mx/pdf/acm/v75s3/v75s3a15.pdf

  16. López J. Torres S, Conde H, Hernández M, Castro J, Aroche R. Linfoma cardiaco primario: Presentación de un caso. Rev Cubana Cardiol Cir Cardiovasc 2010; 16(4):485-90. Texto libre en http://www.revcardiologia. sld.cu/index.php/revcardiologia/article/view/232/178

  17. Canales M, Coya J. PET en linfomas; a quien, cuando y para que. Hematológica/edición española 2008; 9(1):28-33.

  18. García J, Rodríguez A, Cabrera A. Tomografía por emisión de positrones de cuerpo completo (PET/ TAC) con 18F-fl uorodesoxiglucosa. Rev Esp Med Nucl 2009;28(2):85-9.

  19. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117-26. Texto libre en http://jco. ascopubs.org/content/23/18/4117.long

  20. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-91.




2020     |     www.medigraphic.com